# Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion

> **NCT00498160** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Talaris Therapeutics Inc.** · enrollment: 38 (actual)

## Conditions studied

- Renal Failure

## Interventions

- **BIOLOGICAL:** Enriched Hematopoietic Stem Cell Infusion

## Key facts

- **NCT ID:** NCT00498160
- **Lead sponsor:** Talaris Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-01
- **Primary completion:** 2024-08
- **Final completion:** 2024-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2022-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00498160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00498160, "Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00498160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*